黑料网

Carcinoembryonic antigen; Glycoprotein; Cancer diagnosis

Introduction

Carcinoembryonic Antigen (CEA) is a biomarker that has played a pivotal role in the field of oncology since its discovery in the mid- 20th century. Initially identified as a product of fetal gut tissue and later recognized for its association with certain malignancies, CEA has emerged as a valuable tool in cancer research, diagnosis, and management. This multifaceted glycoprotein has drawn significant attention due to its differential expression in various cancer types, particularly in colorectal carcinoma, and its potential clinical applications extend beyond diagnosis to include prognostication, monitoring treatment response, and even targeted therapy [1]. In this comprehensive review, we delve into the intricate world of CEA, exploring its molecular characteristics, physiological functions, and clinical implications. We will discuss the structure of CEA, its normal expression in healthy tissues, and the mechanisms underlying its upregulation in cancer. Moreover, we will examine its diagnostic utility in different malignancies, evaluating its sensitivity, specificity, and limitations as a tumor marker. Additionally, we will explore the evolving role of CEA in personalized cancer treatment, including its potential as a therapeutic target and its use in guiding treatment decisions.

Through a comprehensive examination of CEA, this review aims to provide a thorough understanding of its significance in oncology, shedding light on its past, present, and future contributions to the field of cancer research and patient care [2].

Results and Discussion

Carcinoembryonic Antigen (CEA) has been extensively investigated in a variety of clinical and research settings, with notable findings and implications in oncology. In this section, we present the key results and discuss their significance in the context of CEA’s role as a tumor marker, its clinical applications, and its potential as a therapeutic target [3].

Diagnostic utility of CEA: CEA has proven to be a valuable tool in the diagnosis of several malignancies, particularly colorectal carcinoma. Elevated serum CEA levels have been consistently associated with the presence of colorectal cancer. Multiple studies have reported its sensitivity and specificity in the diagnosis of this malignancy, aiding in early detection and monitoring of disease progression. However, it is important to acknowledge that CEA is not cancer-specific and can also be elevated in various non-malignant conditions, such as inflammatory bowel disease and liver disease [4, 5].

Prognostic significance: Beyond its diagnostic role, CEA has demonstrated prognostic value in cancer patients. Elevated preoperative CEA levels have been linked to more advanced disease stages and poorer overall survival rates. Monitoring postoperative CEA levels can serve as an indicator of treatment efficacy and recurrence risk. However, the precise cutoff values for risk stratification vary among different cancer types and require careful consideration in clinical practice [6].

Monitoring treatment response: CEA levels have been employed to monitor treatment response in patients undergoing cancer therapy. A decline in CEA levels during treatment often corresponds to a positive response, while increasing levels may indicate disease progression or treatment resistance. This dynamic assessment of CEA can guide clinicians in adapting treatment strategies and optimizing patient care [7-9].

Therapeutic potential: In recent years, CEA has garnered attention as a potential therapeutic target. Monoclonal antibodies targeting CEA have been developed and tested in clinical trials. These immunotherapeutic approaches hold promise for selectively targeting cancer cells overexpressing CEA, thereby minimizing collateral damage to healthy tissues. However, challenges remain in optimizing the efficacy and safety of CEA-targeted therapies [10].

Future directions: While CEA has undoubtedly contributed to our understanding of cancer biology and clinical management, ongoing research aims to refine its utility further. This includes identifying novel biomarkers to complement CEA in cancer diagnosis and prognosis [11]. Additionally, advances in molecular profiling and personalized medicine may enable more precise utilization of CEA in treatment decisions. In conclusion, Carcinoembryonic Antigen (CEA) has evolved into a versatile biomarker with substantial clinical relevance in oncology. Its diagnostic, prognostic, and therapeutic applications continue to shape cancer research and patient care. However, the challenges associated with its specificity and the need for further refinement of therapeutic approaches underscore the ongoing importance of CEA research in the field of oncology [12].

Conclusion

Carcinoembryonic Antigen (CEA) has traversed a remarkable journey from its discovery as a product of fetal gut tissue to its pivotal role in modern oncology. As this review has illustrated, CEA is a multifaceted glycoprotein with significant clinical implications, serving as a valuable tool for cancer diagnosis, prognosis, treatment monitoring, and even as a potential therapeutic target. The diagnostic utility of CEA, particularly in colorectal carcinoma, cannot be overstated. Its ability to aid in early cancer detection, assess disease burden, and monitor response to treatment has revolutionized clinical practice. Nevertheless, it is essential to recognize the limitations of CEA, including its lack of cancer specificity and its elevation in benign conditions. Hence, its interpretation must be nuanced and integrated into a comprehensive clinical assessment.

The prognostic significance of CEA, as demonstrated by numerous studies, underscores its role in predicting disease outcomes. Elevated preoperative CEA levels serve as a valuable indicator of disease aggressiveness and patient prognosis. Postoperative monitoring of CEA levels provides critical insights into treatment efficacy and recurrence risk. The evolving landscape of cancer therapeutics has brought CEA into the spotlight as a potential target for immunotherapy. Monoclonal antibodies directed against CEA have entered clinical trials, offering promise in the realm of precision medicine. Nevertheless, challenges in optimizing the safety and efficacy of CEA-targeted therapies persist.

Looking ahead, the future of CEA research is filled with exciting possibilities. The discovery of novel biomarkers that complement CEA may enhance diagnostic accuracy and refine prognostic assessments. Advances in genomics and proteomics may facilitate more precise utilization of CEA in treatment decisions, fostering a new era of personalized oncology. In conclusion, Carcinoembryonic Antigen (CEA) has left an indelible mark on the landscape of cancer research and clinical practice. Its journey from a fetal marker to a versatile tool in oncology underscores the resilience and adaptability of science. While challenges persist, the enduring quest to unravel the mysteries of CEA and its evolving applications reaffirm its significance as a beacon of hope in the fight against cancer. As we embark on the next chapter of CEA research, we do so with optimism, armed with the knowledge that every discovery brings us one step closer to conquering this formidable adversary.

Acknowledgement

None

Conflict of Interest

None

References

1. Banerjee AK, Galloway SW, Kingsnorth (1994) . BrJSurg 81:1096-103.

   , ,

2. Walsh CJ, Leeper-Woodford SK, Carey PD, Cook DJ, Bechard DE, et al. (1991) CD18 adhesion receptors, tumor necrosis factor, and neutropenia during septic lung injury. J Surg Research 50:323-329.

, ,

3. Corfield AP, Cooper MJ, Williamson RCN (1985) Gut 26: 724-9.

, ,

4. Sandoval DIANA, Gukovskaya ANNA, Reavey PATRICK, Gukovsky SOFIYA, Sisk ABBYANN, et al. (1996) . Gastroenterology 111:1081-1091.

, ,

5. Formela LJ, Galloway SW, Kingsnorth AN (1995) . BrJSurg 82: 6-13.

, ,

6. Leach SD, Gorelick FS, Modlin IM (1990) Ann Surg 212: 109-13.

, ,

7. Steer ML, Meldolesi J (1987) . NEngl JMed 316: 144-50.

, ,

8. Warshaw AL (1993) . Gastroenterology 104: 1216-9.

, ,

9. Baj J, Radzikowska E, Maciejewski M, Dąbrowski K, Torres K, et al. (2017) . Pol Prz Chir 89:31-3810.

, ,

10. Bj Nes T, Riedel B, Schjott J (2021) Pharmacol Res 165:105475.

, ,

11. Boissenot, Boissenot T, Bordat A, Fattal E, Tsapis N (2016) J Control Release 241:144-163.

, ,

12. Borrelli MJ, Borrelli WD, O'brien E, Hamilton ML, Oelze J, et al (2012) J Vasc Interv Radiol 23:1677-1684.

, ,